Articles related to COMBINATION THERAPY

“Patients treated in the Optune Pax arm had a median time to pain progression of 15.2 months compared to 9.1 months.” — PANOVA-3 Trial, FDA Approval Announcement

Castalin can boost the effectiveness of CHK1 inhibitors, a class of drugs currently in phase 1 clinical trials. When tested in cellular models of triple-negative breast cancer, one of the most aggressive forms of the disease, Castalin was shown to enhance the action of these inhibitors.

“Progress is sort of stepwise. How do we make things better? And what we see with FLAURA2 is that we do see an improvement in survival – a meaningful improvement in survival.” – Dr. Stephen Liu

Fixed-dose combination achieved 71% target LDL attainment versus 25% with ezetimibe alone in high-risk cardiovascular patients.

The emergence of novel agents including BTK degraders, next-generation BCL2 inhibitors, and optimized combination approaches is reshaping the CLL treatment landscape, with multiple trials demonstrating high uMRD rates, improved progression-free survival, and manageable toxicity profiles across different patient populations.

Long-term follow-up data demonstrate a significant overall survival advantage with combination therapy, showing a hazard ratio of 0.54 (95% CI 0.31-0.95) for radiation plus temozolomide versus radiation alone in grade II gliomas.